The company is looking to work out an arrangement with the U.K. government that would see higher drug prices in exchange for Lilly to continue its U.K. investments, according to a report in The Financial Times. More: Lilly presses for
read moreWith a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an expansion and putting more color on its filing plans with the FDA. More: United plots Tyvaso FDA filing after
read morePromotional materials for a handful of biologics have found their way into the FDA’s hot seat. More: BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters Source: fierce
read moreAfter notching a phase 2 trial win, Idorsia’s insomnia med Quviviq is one step closer to potentially becoming a first-in-class treatment for children. More: Idorsia eyes pediatric insomnia use with midstage trial win for sleep med Quviviq Source: fierce
read moreThe labor union of Samsung Biologics has secured the votes needed to strike, signaling a potential escalation in an impasse over what the union has branded “[u]nresolved governance failures and rigid labor policies” at the company. More: Samsung Biologics union
read more
Phase 3 studies report meaningful reductions in exacerbations across broad patient groups More: Tozorakimab shows significant benefit in two major COPD trials Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals